Extramedullary involvement (or extramedullary disease, EMD) represents an aggressive
form of multiple myeloma (MM), characterized by the ability of a clone and/or subclone to …

Recent advances in the treatment of multiple myeloma have increased the need for accurate
diagnosis of the disease. The detection of bone and bone marrow lesions is crucial in the …

PURPOSE The MASTER trial combined daratumumab, carfilzomib, lenalidomide, and
dexamethasone (Dara-KRd) in newly diagnosed multiple myeloma (NDMM), using minimal …

Since the publication of the article entitled “Multiple Myeloma: EHA-ESMO Clinical Practice
Guidelines for Diagnosis, Treatment and Follow-up”(HemaSphere. 2021; 5: e528) …

Multiple myeloma (MM) accounts for 1% of all cancers and $10% of all haematological
malignancies. The incidence in Europe is 4.5–6.0/100 000/year with a median age at …

Extramedullary multiple myeloma (EMM) is an aggressive subentity of multiple myeloma,
characterized by the ability of a subclone to thrive and grow independent of the bone …

Metabolic adjustments are necessary for the initiation, proliferation, and spread of cancer
cells. Although mitochondria have been shown to move to cancer cells from their …

Solitary plasmacytoma is an infrequent form of plasma cell dyscrasia that presents as a
single mass of monoclonal plasma cells, located either extramedullary or intraosseous. In …

BACKGROUND. Multiple myeloma is usually fatal due to serial relapses that become
progressively refractory to therapy. CD19 is typically absent on the dominant multiple …

Background Sinonasal neoplasms, whether benign and malignant, pose a significant
challenge to clinicians and represent a model area for multidisciplinary collaboration in …